named lectures at various universities and research institutes. Dr. Bell received his Sc.D. in chemical engineering from the Massachusetts Institute of Technology in 1967.

Charles P. Casey (NAS) is Homer B. Adkins Emeritus Professor of Chemistry at the University of Wisconsin-Madison. His research lies at the interface between organometallic chemistry and homogeneous catalysis, and his group studies the mechanisms of homogeneously catalyzed reactions. Dr. Casey is author of more than 250 papers in organometallic chemistry. He has served as chairman of the Organometallic Subdivision and of the Inorganic Chemistry Division of the American Chemical Society (ACS) and as president of ACS (in 2004), and he is a member of the editorial advisory board of the Journal of the American Chemical Society. In 1993, he was elected to the National Academy of Sciences and to the American Academy of Arts and Sciences. Dr. Casey received the ACS A.C. Cope Scholar Award in 1988 and Award in Organometallic Chemistry in 1991. He received his B.S. from St. Louis University and his Ph.D. from the Massachusetts Institute of Technology.

Michael J. Clarke was the program director for inorganic, bioinorganic, and organometallic chemistry at the National Science Foundation and holds a permanent position as a professor of chemistry at Boston College. His research focus is on how unusual transition-metal ions interact with biologic systems. He has designed and discovered new bioactive metal-containing agents for anticancer and other types of therapy, developed the activation-by-reduction hypothesis for metal anticancer agents, and participated in developing the concept that ruthenium anticancer compounds preferentially enter cancer cells by binding to transferrin. He was among the first to explore how ruthenium complexes bind to DNA and developed some of the early fundamental chemistry of technetium relevant to its use in radioimaging agents. He continues to explore how metal ions affect DNA, RNA, coenzymes, and important sulfur-containing polypeptides, such as glutathione. Dr. Clarke is interested in how nitrosyl ruthenium compounds can affect the strengthening of neuronal synapses through the release of nitric oxide at the neuronal site.

Anthony Cugini serves as director of the Department of Energy National Energy Technology Laboratory (NETL) Office of Research and Development (ORD), which comprises the on-site research personnel and laboratories in Morgantown, West Virginia; Pittsburgh, Pennsylvania; and Albany, Oregon. Before being named director of ORD, Dr. Cugini served as focus area leader of the NETL Computational and Basic Sciences Focus Area. During his tenure as focus area leader, NETL strengthened its position in computational research ranging from computational chemistry through larger-scale process modeling. Before coming to NETL in 1987, Dr. Cugini worked at Procter and Gamble and Gulf Research. At NETL, he has served primarily in ORD. Dr. Cugini has had a